Abstract
Drug discovery is a complex and costly endeavor, requiring multidisciplinary know-how, interdisciplinary collaboration, tenacity, and a bit of luck. For these reasons, the search for new chemical agents to treat human disease has traditionally been undertaken only within the walls of industry. While the pharmaceutical industry is often successful where it focuses its attention, it generally focuses only on those areas that are allowed by corporate financial realities. Sadly, this means that diseases effecting small populations of patients may go untreated. As a society we should not be content with this situation and must make a priority of the development of new models that will allow and encourage drug discovery in disease areas that are neglected by pharma. In this presentation, I will describe one such model that has been established to find treatments for neurodegenerative diseases.
Keywords: Harvard Center for Neurodegeneration and Repair, Drug Discovery, Medicinal Chemistry, Laboratory for Drug Discovery in Neurodegeneration, pharmaceutical company
Current Alzheimer Research
Title: A New Model for Academics Based Drug Discovery
Volume: 4 Issue: 5
Author(s): Ross L. Stein
Affiliation:
Keywords: Harvard Center for Neurodegeneration and Repair, Drug Discovery, Medicinal Chemistry, Laboratory for Drug Discovery in Neurodegeneration, pharmaceutical company
Abstract: Drug discovery is a complex and costly endeavor, requiring multidisciplinary know-how, interdisciplinary collaboration, tenacity, and a bit of luck. For these reasons, the search for new chemical agents to treat human disease has traditionally been undertaken only within the walls of industry. While the pharmaceutical industry is often successful where it focuses its attention, it generally focuses only on those areas that are allowed by corporate financial realities. Sadly, this means that diseases effecting small populations of patients may go untreated. As a society we should not be content with this situation and must make a priority of the development of new models that will allow and encourage drug discovery in disease areas that are neglected by pharma. In this presentation, I will describe one such model that has been established to find treatments for neurodegenerative diseases.
Export Options
About this article
Cite this article as:
Stein L. Ross, A New Model for Academics Based Drug Discovery, Current Alzheimer Research 2007; 4 (5) . https://dx.doi.org/10.2174/156720507783018280
DOI https://dx.doi.org/10.2174/156720507783018280 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Aluminum Vaccine Adjuvants: Are they Safe?
Current Medicinal Chemistry GABA Receptors: Pharmacological Potential and Pitfalls
Current Pharmaceutical Design Beyond Monoamines-Novel Targets for Treatment-Resistant Depression: A Comprehensive Review
Current Neuropharmacology Analysis of Adverse Events Related to 720 Cases of Neural Progenitor Cell Transplantation
CNS & Neurological Disorders - Drug Targets Protein Aggregation and Self Assembly in Health and Disease
Current Proteomics Etiopathogenesis, Classical Immunotherapy and Innovative Nanotherapeutics for Inflammatory Neurological Disorders
Current Nanoscience Recent Patents on Drugs Addressing Neurodegenerative Diseases
Recent Patents on Biomarkers Emerging Methods for Structural Analysis of Protein Aggregation
Protein & Peptide Letters Neurotransmitters and Microglial-Mediated Neuroinflammation
Current Protein & Peptide Science Driving Cellular Plasticity and Survival Through the Signal Transduction Pathways of Metabotropic Glutamate Receptors
Current Neurovascular Research Brain: The Potential Diagnostic and Therapeutic Target for Glaucoma
CNS & Neurological Disorders - Drug Targets From Preclinical to Clinical Trials: An Update on Potential Therapies for Huntington’s Disease
Current Psychopharmacology DNA Secondary Structure at Chromosomal Fragile Sites in Human Disease
Current Genomics Potential for Stem Cells Therapy in Alzheimer’s Disease: Do Neurotrophic Factors Play Critical Role?
Current Alzheimer Research Neurological Disorders in Medical Use of <i>Cannabis</i>: An Update
CNS & Neurological Disorders - Drug Targets Spin Trapping: An Essential Tool for the Study of Diseases Caused by Oxidative Stress
Current Topics in Medicinal Chemistry Regulation and Quantification of Cellular Mitochondrial Morphology and Content
Current Pharmaceutical Design SUMOylation in Neurological Diseases
Current Molecular Medicine Involvement of the Mitochondrial Benzodiazepine Receptor in Traumatic Brain Injury: Therapeutic Implications
CNS & Neurological Disorders - Drug Targets Primary Progressive Aphasia-Defining Genetic and Pathological Subtypes
Current Alzheimer Research